Neptune Interlon (08329): The controlling shareholder, Neptune Biotech, received a decision from the Shenzhen Securities Regulatory Bureau

According to the Zhitong Finance App, Haiwang Interlon (08329) issued an announcement. Shenzhen Haiwang Biotechnology Co., Ltd. (Haiwang Biotech), the controlling shareholder of the Company, received a decision from the Shenzhen Regulatory Bureau (Shenzhen Securities Regulatory Bureau) of the China Securities Regulatory Commission, which decided to take corrective regulatory measures against Haiwang Biotech and its controlling shareholders. The decision stated that Haiwang Biotech should take active measures to clear the occupied funds and protect the interests of listed companies and small and medium shareholders; its controlling shareholders should effectively fulfill their main responsibilities and actively raise and repay the occupied funds. Haiwang Biotech and its controlling shareholders should carefully learn lessons, strengthen their study of securities laws and regulations, and prevent the recurrence of such irregularities. All occupied funds should be returned within six months from the date the decision was received, and a written report should be submitted to the Shenzhen Securities Regulatory Bureau after the rectification is completed.